HGEN - COVID-19 treatment developers under pressure on positive COVID-19 vaccine data

Pfizer and BioNTech's announcement that their COVID-19 vaccine candidate showed 90% efficacy based on a preliminary analysis of results from a pivotal study has stoked selling in therapy developers. If the higher-than-expected efficacy holds, herd immunity in the general population could potentially be reached reasonably quickly, dampening demand for treatments, including antibodies and convalescent plasma.Today's action exemplifies the volatility risk in the COVID-19 space that SA reported in August.Selected tickers: Vir Biotechnology ([[VIR]] -19.1%), Regeneron Pharmaceuticals ([[REGN]] -3.6%), Eli Lilly ([[LLY]] -0.2%), Kamada Ltd. ([[KMDA]] -8.6%), Xbiotech ([[XBIT]] -0.2%), ADMA Biologics ([[ADMA]] -4.2%), Twist Bioscience ([[TWST]] -8.0%), Humanigen ([[HGEN]] -29.6%).

For further details see:

COVID-19 treatment developers under pressure on positive COVID-19 vaccine data